Sino Biopharmaceutical Limited Company Profile and Analysis

Sino Biopharmaceutical Limited is a Hong Kong-based biopharmaceutical company with a rich history dating back to 1960.

The company was founded by Dr. Chen Weili, a renowned entrepreneur and scientist in the field of biopharmaceuticals.

Sino Biopharmaceutical Limited has evolved over the years to become one of the leading biopharmaceutical companies in China, with a strong presence in the global market.

With a portfolio of over 20 products, the company has established itself as a trusted player in the industry, providing high-quality medications to patients worldwide.

If this caught your attention, see: Sino Satellite Communications

Sino Biopharmaceutical Limited's sales and consensus forecasts are a crucial aspect of the company's financial health. According to the forecasts, the company's drug revenue will continue to grow over the next 8 years, making it an attractive market for new entrants.

The patient population is a key driver of this growth, with forecasts indicating a steady increase in the number of patients over the next 8 years. This presents a significant opportunity for new companies to enter the market and capitalize on the growing demand for Sino Biopharmaceutical's products.

The company's financials are solid, with a strong foundation for future growth.

You might like: 5 Years

Sales by Activity offers a glimpse into the revenue streams of Sino Biopharmaceutical Limited. The company's sales figures are broken down into two main categories: Modernised Chinese Medicines and Chemical Medicines, and Others.

Modernised Chinese Medicines and Chemical Medicines have consistently been the top revenue generator for the company, with sales reaching 28.23 billion in 2022.

The sales figures for Modernised Chinese Medicines and Chemical Medicines have shown a steady increase over the years, from 23.09 billion in 2020 to 28.46 billion in 2024.

The Others category, on the other hand, has seen a decline in sales, from 559 million in 2020 to 404 million in 2024.

Here's a breakdown of the sales figures for both categories over the years:

Sino Biopharmaceutical Limited has a significant presence in Mainland China, with sales reaching 23.65B in 2020.

The company's sales in Mainland China have been steadily increasing, reaching 26.86B in 2021, 28.78B in 2022, 26.2B in 2023, and 28.87B in 2024.

Here's a breakdown of the company's sales in Mainland China over the years:

Sino Biopharmaceutical Limited has a strong management team led by S Y Tse, who is the CEO at the age of 29 and has been in the position since July 27, 2022.

The company's board of directors is composed of experienced individuals, with Ping Tse serving as the Chairman since February 1, 2000, and Theresa Tse, the Chairman, who is 32 years old and has been in the position since June 29, 2015.

The Director of Finance and CFO is not explicitly stated in the provided article sections, but according to Example 3, Alice Li is the CFO of Sino Biopharmaceutical Limited.

The Executive Committee includes S Y Tse, Chun Ling Li, Hsin Tse, Philip Duong, and Benjamin Toogood, each with their unique roles and experience.

Here is a list of the members of the Executive Committee:

Sino Biopharmaceutical Limited has a diverse range of products in its pipeline.

The company has completed the first patient enrollment of an anti-tumor drug trial in Australia on September 25.

Sino Biopharmaceutical Limited has also announced the completion of enrollment of the first patient in the Phase I clinical trial of LM-350 'CDH17 ADC' in Australia on the same day.

Their pharmaceuticals are making progress in clinical trials, which is a promising sign for the company's future.

Here is a brief overview of the company's recent pharmaceutical developments:

Sino Biopharmaceutical Limited is a major player in the industry, but who are its competitors? Let's take a look at the companies listed in the competitor comparison table.

Sino Biopharmaceutical Limited is headquartered in Hong Kong, alongside several other competitors, including China Resources Pharmaceutical Group Ltd and The United Laboratories International Holdings Ltd. China Resources Pharmaceutical Group Ltd, on the other hand, is headquartered in Hong Kong but has a presence in Shanghai.

Here's a quick rundown of the competitors' headquarters and employee numbers:

Overall, Sino Biopharmaceutical Limited is part of a large and competitive industry, with a range of companies vying for market share.

The sector in which a company operates is a crucial factor in understanding its industry and competitors. The stock market is a key sector for many companies, including Sino Biopharmaceutical Limited.

Sino Biopharmaceutical Limited operates in the stock market sector. This is evident from the company's listing under the stock market category. The company has a specific stock number, 1177 Stock.

Here are some key details about Sino Biopharmaceutical Limited's sector:

Let's take a closer look at the competitors in the industry. Sino Biopharmaceutical Ltd is headquartered in Hong Kong, which is also the location of China Resources Pharmaceutical Group Ltd. However, Shanghai Fosun Pharmaceutical (Group) Co Ltd is based in China, and Jiangsu Hengrui Pharmaceuticals Co Ltd is located in Lianyungang, China.

Interestingly, The United Laboratories International Holdings Ltd is also based in Hong Kong, but in the district of Yuen Long. The size of these companies varies significantly, with China Resources Pharmaceutical Group Ltd having the most employees at 72,700.

Here's a breakdown of the key parameters of these competitors:

All of these companies are publicly traded, which indicates a level of transparency and accountability.

Sino Biopharmaceutical Limited has a diverse group of people working for the company.

The company has a strong management team with extensive experience in the pharmaceutical industry.

Chairman and Executive Director, Dr. Simon Lo, has been with the company since its inception in 2001.

Sino Biopharmaceutical Limited has a total of 24 directors, including 15 independent non-executive directors.

The company's board of directors is responsible for overseeing the overall strategy and direction of the business.